Y. Ostapenko
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 4
-
- Gastric Cancer Management and Outcomes 6
- Lung Cancer Treatments and Mutations 1
- Co-authors
- Pooja Bhagia (1 shared paper)Lucjan Stanislaw Wyrwicz (1 shared paper)Patricio Eduardo Yanez (1 shared paper)Lin Shen (2 shared papers)Yelena Yuriy Janjigian (2 shared papers)Mehmet Bilici (2 shared papers)Josep M. Tabernero (1 shared paper)Yuxian Bai (1 shared paper)
- Journals
- Annals of Oncology (4 papers)The Lancet Oncology (2 papers)The Lancet (1 paper)Journal of Clinical Oncology (1 paper)ESMO Open (1 paper)
- Partner nations
- UkraineUnited StatesSouth Korea
In The Last Decade
Y. Ostapenko
14 papers receiving 2.7k citations
Y. Ostapenko's Hit Papers
Peers
Comparison fields: 5 of 57
- Hepatology 1.1k
- Oncology 1.2k
- Pulmonary and Respiratory Medicine 599
- Immunology 79
- Cancer Research 44
Countries citing papers authored by Y. Ostapenko
This map shows the geographic impact of Y. Ostapenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Ostapenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Ostapenko more than expected).
Fields of papers citing papers by Y. Ostapenko
This network shows the impact of papers produced by Y. Ostapenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Ostapenko. The network helps show where Y. Ostapenko may publish in the future.
Co-authors
The 22 scholars most cited alongside Y. Ostapenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2022 | 1109 |
| 2 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 522 |
| 3 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 446 |
| 4 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Hit paper breakdown → | 2023 | 325 |
| 5 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Hit paper breakdown → | 2024 | 239 |
| 6 | Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC Hit paper breakdown → | 2025 | 78 |
| 7 | 2024 | 46 | |
| 8 | 2021 | 22 | |
| 9 | 2025 | 14 | |
| 10 | 2023 | 2 | |
| 11 | 2018 | 1 | |
| 12 | 2019 | 1 | |
| 13 | 2019 | 1 | |
| 14 | 2025 | 1 | |
| 15 | 2024 | 0 | |
| 16 | 2024 | 0 |
About Y. Ostapenko
Y. Ostapenko is a scholar working on Hepatology, Pulmonary and Respiratory Medicine, Oncology, Immunology and Epidemiology, having authored 16 papers that have together received 2.8k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Colorectal Cancer Surgical Treatments (2 papers), Lung Cancer Treatments and Mutations (1 paper), Esophageal Cancer Research and Treatment (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Biosimilars and Bioanalytical Methods (1 paper). The work is most often cited by research in Hepatology (1.1k citations), Oncology (1.2k citations), Pulmonary and Respiratory Medicine (599 citations), Immunology (79 citations) and Cancer Research (44 citations). Y. Ostapenko has collaborated with scholars based in Ukraine, United States and South Korea. Frequent co-authors include Pooja Bhagia, Lucjan Stanislaw Wyrwicz, Patricio Eduardo Yanez, Lin Shen, Yelena Yuriy Janjigian, Mehmet Bilici, Josep M. Tabernero, Yuxian Bai, Sara Lonardi and Shukui Qin. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, The Lancet, Journal of Clinical Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.